NZ742447A - Non-human animals having a humanized lymphocyte-activation gene 3 - Google Patents

Non-human animals having a humanized lymphocyte-activation gene 3

Info

Publication number
NZ742447A
NZ742447A NZ742447A NZ74244716A NZ742447A NZ 742447 A NZ742447 A NZ 742447A NZ 742447 A NZ742447 A NZ 742447A NZ 74244716 A NZ74244716 A NZ 74244716A NZ 742447 A NZ742447 A NZ 742447A
Authority
NZ
New Zealand
Prior art keywords
lag
rodent
humanized
polypeptide
gene
Prior art date
Application number
NZ742447A
Other languages
English (en)
Inventor
Andrew J Murphy
Elena Burova
Alexander O Mujica
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of NZ742447A publication Critical patent/NZ742447A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2517/00—Cells related to new breeds of animals
    • C12N2517/02—Cells from transgenic animals

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Environmental Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
NZ742447A 2015-11-20 2016-11-18 Non-human animals having a humanized lymphocyte-activation gene 3 NZ742447A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562258181P 2015-11-20 2015-11-20
US201662370430P 2016-08-03 2016-08-03
PCT/US2016/062733 WO2017087780A1 (en) 2015-11-20 2016-11-18 Non-human animals having a humanized lymphocyte-activation gene 3

Publications (1)

Publication Number Publication Date
NZ742447A true NZ742447A (en) 2022-12-23

Family

ID=57543170

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ742447A NZ742447A (en) 2015-11-20 2016-11-18 Non-human animals having a humanized lymphocyte-activation gene 3

Country Status (26)

Country Link
US (4) US10306874B2 (cg-RX-API-DMAC7.html)
EP (1) EP3376857B1 (cg-RX-API-DMAC7.html)
JP (1) JP6997708B2 (cg-RX-API-DMAC7.html)
KR (1) KR102454546B1 (cg-RX-API-DMAC7.html)
CN (1) CN108366548B (cg-RX-API-DMAC7.html)
AU (1) AU2016358101B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018010158A2 (cg-RX-API-DMAC7.html)
CA (1) CA3003786C (cg-RX-API-DMAC7.html)
CY (1) CY1124171T1 (cg-RX-API-DMAC7.html)
DK (1) DK3376857T3 (cg-RX-API-DMAC7.html)
ES (1) ES2872799T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20210824T1 (cg-RX-API-DMAC7.html)
HU (1) HUE054612T2 (cg-RX-API-DMAC7.html)
IL (1) IL258841B (cg-RX-API-DMAC7.html)
LT (1) LT3376857T (cg-RX-API-DMAC7.html)
MX (1) MX2018005389A (cg-RX-API-DMAC7.html)
NZ (1) NZ742447A (cg-RX-API-DMAC7.html)
PL (1) PL3376857T3 (cg-RX-API-DMAC7.html)
PT (1) PT3376857T (cg-RX-API-DMAC7.html)
RS (1) RS61866B1 (cg-RX-API-DMAC7.html)
RU (1) RU2745403C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201803409UA (cg-RX-API-DMAC7.html)
SI (1) SI3376857T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202100299T1 (cg-RX-API-DMAC7.html)
WO (1) WO2017087780A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201802717B (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE067123T2 (hu) 2014-12-09 2024-10-28 Regeneron Pharma Humanizált differenciációs klaszter 274 génnel rendelkezõ nem humán állatok
JP6997708B2 (ja) 2015-11-20 2022-02-04 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化されたｌｙｍｐｈｏｃｙｔｅ－ａｃｔｉｖａｔｉｏｎ ｇｅｎｅ ３遺伝子を有する非ヒト動物
AU2017228293B2 (en) 2016-02-29 2023-05-25 Regeneron Pharmaceuticals, Inc. Rodents having a humanized Tmprss gene
US10912287B2 (en) 2016-06-28 2021-02-09 Biocytogen Pharmaceuticals (Beijing) Co., Ltd Genetically modified mice expressing humanized PD-1
CN107815468B (zh) 2016-08-31 2021-03-16 百奥赛图(北京)医药科技股份有限公司 人源化基因改造动物模型的制备方法及应用
CN108070613B (zh) 2016-11-11 2020-03-13 百奥赛图江苏基因生物技术有限公司 人源化基因改造动物模型的制备方法及应用
WO2018086583A1 (en) * 2016-11-11 2018-05-17 Beijing Biocytogen Co., Ltd Genetically modified non-human animal with human or chimeric lag-3
JP7278978B2 (ja) * 2017-06-27 2023-05-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化ａｓｇｒ１座位を含む非ヒト動物
BR112020001364A2 (pt) 2017-07-31 2020-08-11 Regeneron Pharmaceuticals, Inc. métodos para testar e modificar a capacidade de uma crispr/cas nuclease.
WO2019028023A2 (en) 2017-07-31 2019-02-07 Regeneron Pharmaceuticals, Inc. METHODS AND COMPOSITIONS FOR EVALUATING CRISPR / CAS MEDIATED DISRUPTION OR EXCISION AND CRISPR / CAS INDUCED RECOMBINATION USING IN VIVO EXOGENIC DONOR NUCLEIC ACID
EP4276185A3 (en) 2017-09-29 2024-02-21 Regeneron Pharmaceuticals, Inc. Rodents comprising a humanized ttr locus and methods of use
WO2019072241A1 (en) 2017-10-13 2019-04-18 Beijing Biocytogen Co., Ltd NON-HUMAN ANIMAL GENETICALLY MODIFIED WITH PD-1 HUMAN OR CHIMERIC
CN109666701B (zh) * 2017-10-13 2021-08-24 百奥赛图(北京)医药科技股份有限公司 一种pd-1基因修饰人源化动物模型的构建方法及其应用
IL274740B2 (en) * 2017-11-30 2024-06-01 Regeneron Pharma Non-human animals comprising a humanized trkb locus
WO2019183123A1 (en) 2018-03-19 2019-09-26 Regeneron Pharmaceuticals, Inc. Transcription modulation in animals using crispr/cas systems
CA3093850A1 (en) 2018-03-26 2019-10-03 Regeneron Pharmaceuticals, Inc. Humanized rodents for testing therapeutic agents
FI3823443T3 (fi) 2018-07-16 2024-07-25 Regeneron Pharma Ditra-taudin jyrsijämallit ja niiden käyttö
CN111304247B (zh) 2018-12-20 2021-03-16 百奥赛图江苏基因生物技术有限公司 人源化lag-3基因改造动物模型的制备方法及应用
CN109929875B (zh) * 2019-03-12 2021-02-19 江苏集萃药康生物科技股份有限公司 一种lag3基因人源化动物模型的构建方法及其应用
IL286905B2 (en) 2019-04-04 2024-06-01 Regeneron Pharma Non-human animals containing the human coagulation factor 12 locus
US11891618B2 (en) 2019-06-04 2024-02-06 Regeneron Pharmaceuticals, Inc. Mouse comprising a humanized TTR locus with a beta-slip mutation and methods of use
US11622547B2 (en) 2019-06-07 2023-04-11 Regeneran Pharmaceuticals, Inc. Genetically modified mouse that expresses human albumin
CN115175559A (zh) 2020-01-28 2022-10-11 瑞泽恩制药公司 包含人源化pnpla3基因座的非人动物及其使用方法
CN116075221A (zh) * 2020-04-21 2023-05-05 瑞泽恩制药公司 具有人源化cxcl13基因的非人动物
WO2025163140A1 (en) * 2024-02-02 2025-08-07 Vacara Ab Physiologic humanized mice for studies of mhc class ii function

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100257466B1 (ko) * 1994-05-06 2000-07-01 레지날드 쇼트버그 에스. 안토니우스-소도 Lag-3의 가용성 폴리펩타이드 절편 및 생산 방법 치료 조성물, 항-이디오타입 항체
US5670356A (en) 1994-12-12 1997-09-23 Promega Corporation Modified luciferase
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
EP1897548B2 (en) * 2003-02-28 2024-05-22 The Johns Hopkins University T cell regulation
EP1802193B1 (en) 2004-10-19 2014-04-30 Regeneron Pharmaceuticals, Inc. Method for generating a mouse homozygous for a genetic modification
AR072999A1 (es) * 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
RU2425880C2 (ru) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
US8354389B2 (en) 2009-08-14 2013-01-15 Regeneron Pharmaceuticals, Inc. miRNA-regulated differentiation-dependent self-deleting cassette
ES2700852T3 (es) 2009-10-06 2019-02-19 Regeneron Pharma Ratones modificados genéticamente e injerto
US20130061340A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc. Identification and Enrichment of Cell Subpopulations
KR102256316B1 (ko) 2011-02-15 2021-05-28 리제너론 파마슈티칼스 인코포레이티드 인간화된 ｍ－ｃｓｆ 마우스
ES2741649T3 (es) 2011-10-28 2020-02-11 Regeneron Pharma Ratones con complejo mayor de histocompatibilidad modificado genéticamente
ES2858978T3 (es) 2011-10-28 2021-09-30 Regeneron Pharma Ratones con receptores de linfocitos T genéticamente modificados
CN104039133B (zh) 2011-10-28 2018-05-04 瑞泽恩制药公司 表达嵌合主要组织相容性复合物(mhc)ii类分子的基因修饰小鼠
CA2853731C (en) 2011-10-28 2021-05-18 Regeneron Pharmaceuticals, Inc. Humanized il-6 and il-6 receptor
UY34887A (es) * 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
CN108782459B (zh) 2012-09-07 2021-11-05 再生元制药公司 经遗传修饰的非人动物及其使用方法
WO2014043708A1 (en) * 2012-09-17 2014-03-20 Traber Peter G Method for enhancing specific immunotherapies in cancer treatment
IL299887B2 (en) 2012-11-05 2024-09-01 Regeneron Pharma Genetically modified non-human animals and methods of use thereof
KR102714111B1 (ko) 2013-02-20 2024-10-11 리제너론 파아마슈티컬스, 인크. 사람화된 ｔ-세포 보조-수용체를 발현하는 마우스
HRP20181866T1 (hr) 2013-02-22 2019-01-25 Regeneron Pharmaceuticals, Inc. Miševi koji izražavaju humanizirane komplekse glavne histokompatibilnosti
US20150342163A1 (en) 2013-02-22 2015-12-03 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
KR20200136508A (ko) 2013-04-16 2020-12-07 리제너론 파마슈티칼스 인코포레이티드 랫트 게놈의 표적화된 변형
KR102370419B1 (ko) 2013-09-23 2022-03-04 리제너론 파마슈티칼스 인코포레이티드 인간화된 신호-조절 단백질 유전자를 가지는 비-인간 동물
WO2015077071A1 (en) 2013-11-19 2015-05-28 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized b-cell activating factor gene
DK3129400T3 (da) 2014-04-08 2020-06-08 Regeneron Pharma Ikke-humane dyr med humaniserede Fc-gamma-receptorer
NO2785538T3 (cg-RX-API-DMAC7.html) 2014-05-07 2018-08-04
PT3482629T (pt) 2014-05-19 2021-02-18 Univ Yale Animais não humanos geneticamente modificados que expressam epo humana
BR112016029650A2 (pt) 2014-06-19 2017-10-24 Regeneron Pharma roedor, polipeptídeo pd-1, célula isolada ou tecido de roedor, célula-tronco embrionária de roedor, métodos de produzir um roedor, de reduzir o crescimento de tumor em um roedor, de matar células tumorais em um roedor e de avaliar as propriedades farmacocinéticas de uma droga que direciona pd-1 humano, e, modelo de tumor de roedor?
PL3689140T3 (pl) 2014-11-24 2022-09-05 Regeneron Pharmaceuticals, Inc. Zwierzęta inne niż ludzie eksprymujące humanizowany kompleks CD3
IL286403B2 (en) 2014-12-05 2023-10-01 Regeneron Pharma Non-human animals possess a humanized CLUSTER OF DIFFERENTIATION 47 gene
HUE067123T2 (hu) 2014-12-09 2024-10-28 Regeneron Pharma Humanizált differenciációs klaszter 274 génnel rendelkezõ nem humán állatok
CN107666828B (zh) 2015-04-06 2021-04-09 瑞泽恩制药公司 非人动物中的人源化t细胞介导的免疫应答
JP6997708B2 (ja) 2015-11-20 2022-02-04 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化されたｌｙｍｐｈｏｃｙｔｅ－ａｃｔｉｖａｔｉｏｎ ｇｅｎｅ ３遺伝子を有する非ヒト動物

Also Published As

Publication number Publication date
KR102454546B1 (ko) 2022-10-14
ZA201802717B (en) 2023-05-31
US20210360908A1 (en) 2021-11-25
IL258841A (en) 2018-06-28
IL258841B (en) 2021-04-29
AU2016358101A1 (en) 2018-05-31
CN108366548B (zh) 2021-10-08
CA3003786A1 (en) 2017-05-26
JP2018533963A (ja) 2018-11-22
BR112018010158A2 (pt) 2018-11-21
US20170142943A1 (en) 2017-05-25
US11102961B2 (en) 2021-08-31
CY1124171T1 (el) 2022-05-27
KR20180083381A (ko) 2018-07-20
US20190320632A1 (en) 2019-10-24
PT3376857T (pt) 2021-05-27
EP3376857B1 (en) 2021-02-24
LT3376857T (lt) 2021-06-25
MX2018005389A (es) 2018-09-05
SI3376857T1 (sl) 2021-09-30
AU2016358101B2 (en) 2022-12-01
SMT202100299T1 (it) 2021-07-12
SG11201803409UA (en) 2018-05-30
ES2872799T3 (es) 2021-11-02
HRP20210824T1 (hr) 2021-07-09
RU2018117944A (ru) 2019-12-20
PL3376857T3 (pl) 2021-09-13
HK1253683A1 (en) 2019-06-28
JP6997708B2 (ja) 2022-02-04
US20240397919A1 (en) 2024-12-05
HUE054612T2 (hu) 2021-09-28
WO2017087780A1 (en) 2017-05-26
CN108366548A (zh) 2018-08-03
US12096754B2 (en) 2024-09-24
DK3376857T3 (da) 2021-05-25
US10306874B2 (en) 2019-06-04
EP3376857A1 (en) 2018-09-26
RU2745403C2 (ru) 2021-03-24
RU2018117944A3 (cg-RX-API-DMAC7.html) 2020-04-06
CA3003786C (en) 2023-09-12
RS61866B1 (sr) 2021-06-30

Similar Documents

Publication Publication Date Title
NZ742447A (en) Non-human animals having a humanized lymphocyte-activation gene 3
Lommel et al. Protein O-mannosylation is crucial for E-cadherin–mediated cell adhesion
US11723348B2 (en) Genetically modified mice expressing humanized CD47
Zhao et al. Female-to-male sex reversal in mice caused by transgenic overexpression of Dmrt1
Li et al. The implication and significance of beta 2 microglobulin: a conservative multifunctional regulator
Suemizu et al. A basolateral sorting motif in the MICA cytoplasmic tail
Barclay et al. The interaction between signal regulatory protein alpha (SIRPα) and CD47: structure, function, and therapeutic target
Muramatsu Basigin (CD147), a multifunctional transmembrane glycoprotein with various binding partners
Tunquist et al. Loss of AKAP150 perturbs distinct neuronal processes in mice
US20200231686A1 (en) Gprc5d chimeric antigen receptors and cells expressing the same
Li et al. Structure of natural killer cell receptor KLRG1 bound to E-cadherin reveals basis for MHC-independent missing self recognition
Moody et al. Developmentally regulated glycosylation of the CD8αβ coreceptor stalk modulates ligand binding
Kwong et al. Signal‐regulatory protein α from the NOD mouse binds human CD 47 with an exceptionally high affinity–implications for engraftment of human cells
East et al. A targeted deletion in the endocytic receptor gene Endo180 results in a defect in collagen uptake
Rossi et al. Clustering of pre-B cell integrins induces galectin-1-dependent pre-B cell receptor relocalization and activation
FI3808775T3 (fi) Ei-ihmiseläimiä, joilla on humanisoitu erilaistumisklusteri 274 -geeni
US20160175459A1 (en) Il-15 and il-15raplha sushi domain based modulokines
JP2018533963A5 (cg-RX-API-DMAC7.html)
Hartmann et al. Elucidating different pattern of immunoregulation in BALB/c and C57BL/6 mice and their F1 progeny
JP2018500896A5 (cg-RX-API-DMAC7.html)
SA516380394B1 (ar) مستقبلات خلايا t لفيروس ورم حليمي 16 e7 مضادة للبشر
WO2017172981A3 (en) Chimeric antigen receptors targeting cancer
JP2018500012A5 (cg-RX-API-DMAC7.html)
RU2017105515A (ru) Сигнальная система
Reed et al. Diglons are heterodimeric proteins composed of IgLON subunits, and Diglon-CO inhibits neurite outgrowth from cerebellar granule cells

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 NOV 2024 BY ANAQUA SERVICES

Effective date: 20231020

LAPS Patent lapsed